FDA Granted Jemperli Regular Approval for dMMR Endometrial Cancer

JHOP - April 2023 Vol 13, No 2 - FDA Oncology Update
CONFIRMATORY APPROVALS

On February 9, 2023, the FDA granted regular approval to dostarlimab-gxly (Jemperli; GlaxoSmithKline), a PD-1 inhibitor, for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, whose disease progressed during or after treatment with a previous platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation.

This latest FDA approval converts the agent’s initial April 2021 accelerated approval to full approval. The April 2021 approval made dostarlimab the first FDA-approved immunotherapy for dMMR advanced endometrial cancer.

Dostarlimab was also previously approved for adult patients with dMMR recurrent or advanced solid tumors whose disease progressed during or after previous treatment and who have no satisfactory alternative treatment options.

The conversion to regular approval was based on additional results from the phase 1 GARNET study (NCT02715284), a multicenter, multicohort, open-label, clinical trial of patients with advanced solid tumors, including an efficacy population of 141 patients with dMMR recurrent or advanced endometrial cancer that progressed during or after a platinum-containing regimen. Patients were excluded from the trial if they had received PD-1/PD-LI–blocking antibodies, other immune checkpoint inhibitors, or had autoimmune diseases requiring systemic immunosuppressant agents within 2 years.

The major efficacy measures included overall response rate (ORR) and duration of response (DOR). The confirmed ORR was 45.4% (95% confidence interval, 37.0-54.0); in addition, 15.6% achieved a complete response and 29.8% had a partial response. The median DOR was not reached: 85.9% of patients had a DOR ≥12 months, and 54.7% of patients had a DOR ≥24 months (range, 1.2+ to 52.8+).

The most common (≥20%) adverse events were fatigue/asthenia, anemia, rash, nausea, diarrhea, constipation, and vomiting. Immune-mediated adverse events can occur, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis with renal dysfunction, and skin adverse reactions.

The recommended dostarlimab-gxly dose and schedule (doses 1-4) is 500 mg every 3 weeks. Subsequent dosing, beginning 3 weeks after dose 4, is 1000 mg every 6 weeks until disease progression or unacceptable toxicity. Dostarlimab-gxly should be administered as an intravenous infusion over 30 minutes.

Related Items
FDA-Approved Nirogacestat Demonstrates Improved Patient Outcomes in Desmoid Tumor Management
Web Exclusives published on February 12, 2024 in FDA Oncology Update
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Web Exclusives published on December 19, 2023 in FDA Oncology Update
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants
JHOP - December 2023 Vol 13, No 6 published on November 17, 2023 in FDA Oncology Update
Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia
JHOP - December 2023 Vol 13, No 6 published on November 3, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: